Renal Denervation vs Pharmacotherapy for Resistant Hypertension: A Meta-Analysis

Journal of Clinical Hypertension

Volumn 18, Issue 8, 2016, Pages 733-740

  Sun, Dongdong ^a   Li, Chuang ^a   Li, Mei ^a   Liu, Jielin ^a   Wen, Shaojun ^a  

^a BEIJING INSTITUTE OF HEART   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CASE CONTROL STUDY; COMPARATIVE EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; FOLLOW UP; HUMAN; KIDNEY DENERVATION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; COMPARATIVE STUDY; FEMALE; HYPERTENSION; INNERVATION; KIDNEY; MALE; PROCEDURES; SYMPATHECTOMY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84981203568     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12742     Document Type: Article

References (40)

1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–223.
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462–1536.
3. Bakris G, Nathan S. Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction? J Am Coll Cardiol. 2014;63:1924–1925.
4. Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet. 2012;380:591–600.
5. Brinkmann J, Heusser K, Schmidt BM, et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension. 2012;60:1485–1490.
6. Fadl EF, Hoffmann P, Fossum E, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62:526–532.
7. Bhatt DL, Bakris GL. The promise of renal denervation. Cleve Clin J Med. 2012;79:498–500.
8. Thukkani AK, Bhatt DL. Renal denervation therapy for hypertension. Circulation. 2013;128:2251–2254.
9. Myat A, Redwood SR, Qureshi AC, et al. Renal sympathetic denervation therapy for resistant hypertension: a contemporary synopsis and future implications. Circ Cardiovasc Interv. 2013;6:184–197.
10. Mahfoud F, Luscher TF, Andersson B, et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149–2157.
11. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–1401.
12. Fadl EF, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63:991–999.
13. Mahfoud F, Urban D, Teller D, et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur Heart J. 2014;35:2224–2231.
14. Rosa J, Widimsky P, Tousek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2015;65:407–413.
15. Pancholy SB, Shantha GP, Patel TM, et al. Meta-analysis of the effect of renal denervation on blood pressure and pulse pressure in patients with resistant systemic hypertension. Am J Cardiol. 2014;114:856–861.
16. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–e526.
17. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed November 9, 2015.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
19. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
20. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
21. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–1909.
22. Zhang ZH, Yang K, Jiang FL, et al. The effects of catheter-based radiofrequency renal denervation on renal function and renal artery structure in patients with resistant hypertension. J Clin Hypertens (Greenwich). 2014;16:599–605.
23. Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60:1163–1170.
24. Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419–424.
25. Ewen S, Mahfoud F, Linz D, et al. Effects of renal sympathetic denervation on exercise blood pressure, heart rate, and capacity in patients with resistant hypertension. Hypertension. 2014;63:839–845.
26. Flack JM, Bhatt DL, Kandzari DE, et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015;9:769–779.
27. Epstein M, de Marchena E. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the “end of the road” for renal denervation? J Am Soc Hypertens. 2015;9:140–149.
28. Lobo MD, de Belder MA, Cleveland T, et al. Joint UK Societies' 2014 consensus statement on renal denervation for resistant hypertension. Heart. 2015;101:10–16.
29. Gaddam K, Pimenta E, Thomas SJ, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010;24:532–537.
30. Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219–227.
31. Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med. 2014;370:1454–1457.
32. Judd EK, Oparil S. Novel strategies for treatment of resistant hypertension. Kidney Int Suppl (2011). 2013;3:357–363.
33. Briasoulis A, Bakris G. Renal denervation after SYMPLICITY HTN-3: where do we go? Can J Cardiol. 2015;31:642–648.
34. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940–1946.
35. Cole CR, Blackstone EH, Pashkow FJ, et al. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med. 1999;341:1351–1357.
36. Miyai N, Arita M, Miyashita K, et al. Blood pressure response to heart rate during exercise test and risk of future hypertension. Hypertension. 2002;39:761–766.
37. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557–1562.
38. Perlini S, Palladini G, Ferrero I, et al. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension. 2005;46:1213–1218.
39. Ukena C, Mahfoud F, Linz D, et al. Potential role of renal sympathetic denervation for the treatment of cardiac arrhythmias. Eurointervention. 2013;9R:R110–R116.
40. Davies JE, Manisty CH, Petraco R, et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol. 2013;162:189–192.